# NRX Pharmaceuticals, Inc.: financial statements, quarterly

NRXP · Nasdaq · CIK 1719406 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nrxp.md) · [Financials](/companies/nrxp/financials.md) · [Filings](/companies/nrxp/filings.md) · [Insiders](/companies/nrxp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nrxp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | [0.0](/filings/0001437749-25-035210.md) | [0.0 d](/filings/0001437749-26-009418.md) | [0.0](/filings/0001437749-26-017397.md) | [0.0](/filings/0001437749-26-028027.md) | [0.2](/filings/0001437749-25-035210.md) | [1.0 d](/filings/0001437749-26-009418.md) | [1.1](/filings/0001437749-26-017397.md) | [1.1](/filings/0001437749-26-028027.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | [0.0](/filings/0001437749-25-035210.md) | [0.0 d](/filings/0001437749-26-009418.md) | [0.0](/filings/0001437749-26-017397.md) | [0.0](/filings/0001437749-26-028027.md) | [0.1](/filings/0001437749-25-035210.md) | [0.4 d](/filings/0001437749-26-009418.md) | [0.6](/filings/0001437749-26-017397.md) | [0.7](/filings/0001437749-26-028027.md) |
| Research and development | $m | [3.3](/filings/0001437749-24-035289.md) | [2.5 d](/filings/0001437749-25-007743.md) | [1.7](/filings/0001437749-25-017252.md) | [2.8](/filings/0001437749-25-027167.md) | [0.6](/filings/0001437749-25-035210.md) | [1.0 d](/filings/0001437749-26-009418.md) | [0.8](/filings/0001437749-26-017397.md) | [1.0](/filings/0001437749-26-028027.md) | [1.4](/filings/0001437749-25-035210.md) | [0.6 d](/filings/0001437749-26-009418.md) | [1.3](/filings/0001437749-26-017397.md) | [2.1](/filings/0001437749-26-028027.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | [2.4](/filings/0001437749-25-035210.md) | [2.6 d](/filings/0001437749-26-009418.md) | [2.9](/filings/0001437749-26-017397.md) | [2.7](/filings/0001437749-26-028027.md) | [2.8](/filings/0001437749-25-035210.md) | [4.6 d](/filings/0001437749-26-009418.md) | [3.8](/filings/0001437749-26-017397.md) | [4.7](/filings/0001437749-26-028027.md) |
| Operating income | $m | [(5.8)](/filings/0001437749-24-035289.md) | [(4.4) d](/filings/0001437749-25-007743.md) | [(6.0)](/filings/0001437749-25-017252.md) | [(7.1)](/filings/0001437749-25-027167.md) | [(3.0)](/filings/0001437749-25-035210.md) | [(2.4) d](/filings/0001437749-26-009418.md) | [(3.8)](/filings/0001437749-26-017397.md) | [(3.7)](/filings/0001437749-26-028027.md) | [(4.0)](/filings/0001437749-25-035210.md) | [(4.6) d](/filings/0001437749-26-009418.md) | [(4.7)](/filings/0001437749-26-017397.md) | [(6.5)](/filings/0001437749-26-028027.md) |
| Interest expense | $m | [0.0](/filings/0001558370-23-019008.md) | [0.1 d](/filings/0001558370-24-004396.md) | [0.2](/filings/0001558370-24-008144.md) | [0.0](/filings/0001437749-25-027167.md) | [0.0](/filings/0001437749-25-035210.md) | [0.0 d](/filings/0001437749-26-009418.md) | [0.0](/filings/0001437749-26-017397.md) | [0.0](/filings/0001437749-26-028027.md) | [0.0](/filings/0001437749-25-035210.md) | [0.7 d](/filings/0001437749-26-009418.md) | [0.2](/filings/0001437749-26-017397.md) | [0.2](/filings/0001437749-26-028027.md) |
| Income tax | $m | [0.0 d](/filings/0001437749-24-035289.md) | [0.0 d](/filings/0001437749-25-007743.md) | [0.0](/filings/0001437749-25-017252.md) | [0.0 d](/filings/0001437749-25-027167.md) | [0.0 d](/filings/0001437749-25-035210.md) | [0.0 d](/filings/0001437749-26-009418.md) | [0.0](/filings/0001437749-26-017397.md) | [0.0](/filings/0001437749-26-028027.md) | [0.0 d](/filings/0001437749-25-035210.md) | [0.0 d](/filings/0001437749-26-009418.md) | [0.0](/filings/0001437749-26-017397.md) | [0.0](/filings/0001437749-26-028027.md) |
| Net income | $m | [(6.1)](/filings/0001437749-24-035289.md) | [(4.3) d](/filings/0001437749-25-007743.md) | [(6.5)](/filings/0001437749-25-035210.md) | [(7.9)](/filings/0001437749-25-035210.md) | [(1.6)](/filings/0001437749-25-035210.md) | [(9.1) d](/filings/0001437749-26-009418.md) | [(5.5)](/filings/0001437749-26-028027.md) | [(17.6)](/filings/0001437749-26-028027.md) | [(5.9)](/filings/0001437749-25-035210.md) | [0.4 d](/filings/0001437749-26-009418.md) | [(1.4)](/filings/0001437749-26-028027.md) | [(16.5)](/filings/0001437749-26-028027.md) |
| Diluted EPS | $ per share | [(0.07)](/filings/0001558370-23-019008.md) | not reported | [(0.74)](/filings/0001558370-24-008144.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.74)](/filings/0001437749-24-035289.md) | not reported | [(0.74)](/filings/0001437749-25-017252.md) | [(0.75)](/filings/0001437749-25-027167.md) | [(0.15)](/filings/0001437749-25-035210.md) | not reported | [(0.34)](/filings/0001437749-26-017397.md) | [(0.98)](/filings/0001437749-26-028027.md) | [(0.27)](/filings/0001437749-25-035210.md) | not reported | [(0.04)](/filings/0001437749-26-017397.md) | [(0.44)](/filings/0001437749-26-028027.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [8.9](/filings/0001558370-23-019008.md) | [4.6](/filings/0001437749-25-007743.md) | [1.3](/filings/0001558370-24-008144.md) | [1.9](/filings/0001437749-24-026847.md) | [1.6](/filings/0001437749-24-035289.md) | [1.4](/filings/0001437749-26-009418.md) | [5.5](/filings/0001437749-25-017252.md) | [2.9](/filings/0001437749-25-027167.md) | [7.2](/filings/0001437749-25-035210.md) | [7.8](/filings/0001437749-26-028027.md) | [6.7](/filings/0001437749-26-017397.md) | [26.7](/filings/0001437749-26-028027.md) |
| Current assets | $m | [13.1](/filings/0001558370-23-019008.md) | [6.9](/filings/0001437749-25-007743.md) | [3.3](/filings/0001558370-24-008144.md) | [4.9](/filings/0001437749-24-026847.md) | [4.1](/filings/0001437749-24-035289.md) | [3.3](/filings/0001437749-26-009418.md) | [7.3](/filings/0001437749-25-017252.md) | [4.6](/filings/0001437749-25-027167.md) | [11.9](/filings/0001437749-25-035210.md) | [8.9](/filings/0001437749-26-028027.md) | [7.4](/filings/0001437749-26-017397.md) | [29.2](/filings/0001437749-26-028027.md) |
| Total assets | $m | [13.1](/filings/0001558370-23-019008.md) | [7.3](/filings/0001437749-25-007743.md) | [3.8](/filings/0001558370-24-008144.md) | [5.3](/filings/0001437749-24-026847.md) | [4.5](/filings/0001437749-24-035289.md) | [3.7](/filings/0001437749-26-009418.md) | [7.6](/filings/0001437749-25-017252.md) | [4.8](/filings/0001437749-25-027167.md) | [15.0](/filings/0001437749-25-035210.md) | [13.0](/filings/0001437749-26-028027.md) | [11.9](/filings/0001437749-26-017397.md) | [34.2](/filings/0001437749-26-028027.md) |
| Current liabilities | $m | [19.3](/filings/0001558370-23-019008.md) | [19.0](/filings/0001437749-25-007743.md) | not reported | not reported | [20.3](/filings/0001437749-24-035289.md) | [21.9](/filings/0001437749-26-009418.md) | [32.8](/filings/0001437749-25-017252.md) | [40.5](/filings/0001437749-25-027167.md) | [40.6](/filings/0001437749-25-035210.md) | [28.6](/filings/0001437749-26-028027.md) | [25.2](/filings/0001437749-26-017397.md) | [33.9](/filings/0001437749-26-028027.md) |
| Total liabilities | $m | [19.3](/filings/0001558370-23-019008.md) | [19.0](/filings/0001437749-25-007743.md) | [18.9](/filings/0001558370-24-008144.md) | [23.7](/filings/0001437749-24-026847.md) | [23.3](/filings/0001437749-24-035289.md) | [26.9](/filings/0001437749-26-009418.md) | [32.8](/filings/0001437749-25-017252.md) | [40.5](/filings/0001437749-25-027167.md) | [40.8](/filings/0001437749-25-035210.md) | [28.9](/filings/0001437749-26-028027.md) | [25.7](/filings/0001437749-26-017397.md) | [34.3](/filings/0001437749-26-028027.md) |
| Long-term debt | $m | [10.1](/filings/0001558370-23-019008.md) | [9.2](/filings/0001558370-24-004396.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [10.1](/filings/0001558370-23-019008.md) | [9.2](/filings/0001558370-24-004396.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(6.2)](/filings/0001437749-24-035289.md) | [(11.7)](/filings/0001437749-26-009418.md) | [(15.1)](/filings/0001437749-25-035210.md) | [(18.4)](/filings/0001437749-25-035210.md) | [(18.8)](/filings/0001437749-25-035210.md) | [(23.2)](/filings/0001437749-26-028027.md) | [(25.2)](/filings/0001437749-26-028027.md) | [(35.6)](/filings/0001437749-26-028027.md) | [(25.8)](/filings/0001437749-25-035210.md) | [(15.9)](/filings/0001437749-26-028027.md) | [(13.8)](/filings/0001437749-26-028027.md) | [(0.2)](/filings/0001437749-26-028027.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(4,564) d](/filings/0001437749-24-035289.md) | [(3,192) d](/filings/0001437749-25-007743.md) | [(3,671)](/filings/0001437749-25-017252.md) | [(2,562) d](/filings/0001437749-25-027167.md) | [(2,306) d](/filings/0001437749-25-035210.md) | [(2,098) d](/filings/0001437749-26-009418.md) | [(3,480)](/filings/0001437749-26-017397.md) | [(4,028) d](/filings/0001437749-26-028027.md) | [(2,891) d](/filings/0001437749-25-035210.md) | [(3,713) d](/filings/0001437749-26-009418.md) | [(4,295)](/filings/0001437749-26-017397.md) | [(8,875) d](/filings/0001437749-26-028027.md) |
| Capital expenditure | $k | [2.0 d](/filings/0001437749-24-035289.md) | [(1.0) d](/filings/0001437749-25-007743.md) | [0.0](/filings/0001437749-25-017252.md) | [0.0 d](/filings/0001437749-24-026847.md) | [0.0 d](/filings/0001437749-24-035289.md) | [0.0 d](/filings/0001437749-25-007743.md) | [0.0](/filings/0001437749-25-017252.md) | [0.0 d](/filings/0001437749-26-028027.md) | not reported | not reported | not reported | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets, us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q2 FY2020 (2020-06-30) | Q3 FY2020 (2020-09-30) | Q1 FY2021 (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [36.7](/filings/0001558370-22-013514.md) | [34.1](/filings/0001558370-22-013518.md) | [35.7](/filings/0001558370-22-008948.md) | [42.5](/filings/0001558370-22-013673.md) | [51.7](/filings/0001558370-22-017772.md) | [63.7](/filings/0001558370-23-009950.md) | [65.7](/filings/0001558370-23-014873.md) | [66.4](/filings/0001558370-23-019008.md) | [6.6](/filings/0001558370-24-008144.md) | [73.2](/filings/0001558370-23-014873.md) | [81.9](/filings/0001558370-23-019008.md) | [8.9](/filings/0001558370-24-008144.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 43,295,767 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001437749-26-028027.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.